AULSF (Austar Lifesciences) EBIT: $8.5 Mil (TTM As of Dec. 2025)


AULSF Austar Lifesciences Ltd AULSF
49 GF Score
Price $0.07
GF Value $0.10
! 6 Warning Signs
View Full Analysis

What is Austar Lifesciences EBIT?

Austar Lifesciences AULSF 49 EBIT is $8.5 Mil as of Dec. 2025. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review.

Austar Lifesciences's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $3.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $8.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Austar Lifesciences's annualized ROC % for the quarter that ended in Dec. 2025 was 1.62%. Austar Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 14.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Austar Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.85%.


Austar Lifesciences  (OTCPK:AULSF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Austar Lifesciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=5.666 * ( 1 - 48% )/( (181.246 + 181.66)/ 2 )
=2.94632/181.453
=1.62 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=282.489 - 78.171 - ( 23.072 - max(0, 152.651 - 208.767+23.072))
=181.246

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Austar Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6.586/( ( (47.154 + max(-18.217, 0)) + (46.149 + max(-32.289, 0)) )/ 2 )
=6.586/( ( 47.154 + 46.149 )/ 2 )
=6.586/46.6515
=14.12 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(46.91 + 31.905 + 16.505) - (78.171 + 0 + 35.366)
=-18.217

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(51.36 + 39.705 + 6.968) - (88.19 + 0 + 42.132)
=-32.289

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Austar Lifesciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=8.452/65.768
=12.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Austar Lifesciences EBIT Related Terms


Austar Lifesciences EBIT Historical Data

* Premium members only.

The historical data trend for Austar Lifesciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Austar Lifesciences EBIT Chart

Austar Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.81 18.52 -2.84 5.27 8.55

Austar Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.90 2.55 2.73 5.16 3.29

AULSF vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Austar Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Austar Lifesciences EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Austar Lifesciences's EV-to-EBIT falls into.


AULSF
49GF Score
Austar Lifesciences Ltd AULSF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Austar Lifesciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $8.5 Mil mean?
Austar Lifesciences (AULSF) has a EBIT of $8.5 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Austar Lifesciences.
Is Austar Lifesciences' EBIT too high?
Austar Lifesciences' current EBIT is $8.5 Mil. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' EBIT compare to ABT and SYK?
Austar Lifesciences' EBIT of $8.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Austar Lifesciences. Austar Lifesciences's current EBIT is $8.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current EBIT of $8.5 Mil. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30% below its estimated fair value. The current EBIT is $8.5 Mil. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current EBIT is $8.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Austar Lifesciences (AULSF) Overvalued in 2026?

Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued. The current stock price of $0.07 is trading 30% below its estimated GF Value™ of $0.10.

Key valuation signals for AULSF:

  • EBIT: $8.5 Mil
  • GF Value™: $0.10 vs. price of $0.07 (30% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Austar Lifesciences Business Description

Other Exchanges 06118:Hong Kong
Address No.1018 Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score

Get the complete analysis for AULSF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price
$0.10
GF Value